Research Report on China Measles, Mumps and Rubella (MMR) Vaccine Market, 2013-2017
Measles, mumps and rubella are major infectious diseases that threaten the health of children. Measles is a kind of acute respiratory infectious disease caused by measles virus with rashes covering the whole body. Mumps is a kind of respiratory infectious disease caused by mumps virus, which can violate organs including various gland tissues, nervous system, liver, kidney, heart, joint, etc. Rubella is a kind of acute respiratory infectious disease caused by rubella virus with light constitutional symptoms and lymphadenectasis behind the ears and on the necks, without koplik spots.
In China, the incidence rate of measles declines constantly in recent years. In 2012, the number of measles patients was 6,183, decreasing by 37.82% YOY, with eight patients died of measles. In 2012, the incidence rate of measles was 4.6/100,000,000, which still lagged far behind the target set by WHO (incidence rate: below 1/100,000,000). In 2012, China's lot released volume of measles vaccines reached 8.651 million person-servings, decreasing by 43.5% YOY.
From 2010 to 2012, China's incidence rate of mumps increased year after year. In 2012, the number of mumps patients was 479,518, increasing by 5.53% YOY; the incidence rate was 354.1/100,000,000 without any death. In 2012, China's lot released volume of mumps vaccines was about 6.883 million person-servings, decreasing by 47% YOY.
In 2012, the number of rubella patients was 40,156 in China, decreasing by 38.74% YOY; the incidence rate was 29.7/100,000,000 and one patient died. In 2012, China's lot released volume of rubella vaccines was about 4.44 million person-servings, decreasing by 6.4% YOY.
Since domestic MMR vaccines were listed in China National Immunization Program in 2008, Chinese government has been providing eligible children with free MMR vaccines. If parents require imported MMR vaccines, it will at their own expenses.
According to long-term trend, MMR vaccines will gradually replace univalent vaccines or bivalent vaccines, becoming the mainstream in the market. During 2010 to 2012, China's lot released volume of MMR vaccines slightly declined, which mainly resulted from the fact that imported MMR vaccines were restricted. Along with the implementation of Pharmacopoeia of China (2010 Version), CFDA has not approved the MMR vaccine of GSK to be sold in China because it contains antibiotics. In 2011, a Chinese law office revealed that the MMR vaccines manufactured by Merck violated the approval process of imported vaccines in China because it lacked alerts in the specification and existed safety risks. During 2011 to 2012, China's legal import volume of MMR vaccines decreased sharply. As a result, China's total lot released volume of MMR vaccines also decreased to some extent.
In recent years, because China's newborn population is 16 million or even more every year, the prospect of MMR vaccines is promising. Although the import of MMR vaccines is restricted in China, many parents still choose imported MMR vaccines for their children out of the safety concern on domestic vaccines. These imported MMR vaccines are sold in some private clinics, which may come from smuggling.
Through this report, readers can acquire the following information:
In China, the incidence rate of measles declines constantly in recent years. In 2012, the number of measles patients was 6,183, decreasing by 37.82% YOY, with eight patients died of measles. In 2012, the incidence rate of measles was 4.6/100,000,000, which still lagged far behind the target set by WHO (incidence rate: below 1/100,000,000). In 2012, China's lot released volume of measles vaccines reached 8.651 million person-servings, decreasing by 43.5% YOY.
From 2010 to 2012, China's incidence rate of mumps increased year after year. In 2012, the number of mumps patients was 479,518, increasing by 5.53% YOY; the incidence rate was 354.1/100,000,000 without any death. In 2012, China's lot released volume of mumps vaccines was about 6.883 million person-servings, decreasing by 47% YOY.
In 2012, the number of rubella patients was 40,156 in China, decreasing by 38.74% YOY; the incidence rate was 29.7/100,000,000 and one patient died. In 2012, China's lot released volume of rubella vaccines was about 4.44 million person-servings, decreasing by 6.4% YOY.
Since domestic MMR vaccines were listed in China National Immunization Program in 2008, Chinese government has been providing eligible children with free MMR vaccines. If parents require imported MMR vaccines, it will at their own expenses.
According to long-term trend, MMR vaccines will gradually replace univalent vaccines or bivalent vaccines, becoming the mainstream in the market. During 2010 to 2012, China's lot released volume of MMR vaccines slightly declined, which mainly resulted from the fact that imported MMR vaccines were restricted. Along with the implementation of Pharmacopoeia of China (2010 Version), CFDA has not approved the MMR vaccine of GSK to be sold in China because it contains antibiotics. In 2011, a Chinese law office revealed that the MMR vaccines manufactured by Merck violated the approval process of imported vaccines in China because it lacked alerts in the specification and existed safety risks. During 2011 to 2012, China's legal import volume of MMR vaccines decreased sharply. As a result, China's total lot released volume of MMR vaccines also decreased to some extent.
In recent years, because China's newborn population is 16 million or even more every year, the prospect of MMR vaccines is promising. Although the import of MMR vaccines is restricted in China, many parents still choose imported MMR vaccines for their children out of the safety concern on domestic vaccines. These imported MMR vaccines are sold in some private clinics, which may come from smuggling.
Through this report, readers can acquire the following information:
- Government Policies and Events in China MMR Vaccine Market
- Supply Status of MMR Vaccines in China
- Market Demand of MMR Vaccines in China
- Major Enterprises Providing MMR Vaccines in China Market
- Factors Influencing the Development of China MMR Vaccine Market
- Prospect of China MMR Vaccine Market, 2013-2017
- Vaccine Manufacturing Enterprises
- Vaccine Trade Enterprises
- Medical Institutions
- Investors and Research Institutes Concerned About Vaccine Industry
1 DEVELOPMENT ENVIRONMENT OF CHINA VACCINE INDUSTRY
1.1 Economic Environment
1.2 Policy Environment
1.3 Chinese Population and the Structure
1.4 Overview on China Medical Industry
1.5 Overview on China Vaccine Market
2 OVERVIEW ON CHINA MMR VACCINE MARKET, 2010-2012
2.1 Epidemic Situation of Measles, Mumps and Rubella in China
2.1.1 Measles
2.1.2 Mumps
2.1.3 Rubella
2.2 MMR Vaccine Overview
2.3 Rules on Vaccination Procedures of China National Immunization Program
3 OVERVIEW ON CHINA MMR VACCINE MARKET, 2010-2012
3.1 Status of Lot Release
3.1.1 Measles Vaccine
3.1.2 Mumps Vaccine
3.1.3 Rubella Vaccine
3.1.4 MMR Vaccine
3.2 Market Scale
4 MAJOR MANUFACTURING ENTERPRISES IN CHINA MMR VACCINE MARKET, 2010-2013
4.1 Shanghai Institute of Biological Products Co., Ltd. (SIBP)
4.1.1 Enterprise Profile
4.1.2 Lot Released Volume of MMR Vaccine
4.1.3 Production Capacity of MMR Vaccine in 2013
4.2.1 Enterprise Profile
4.2.2 Lot Released Volume of MMR Vaccine, 2010-2012
4.2.3 Production Capacity of MMR Vaccine in 2013
4.3 Other Enterprises
5 FORECAST ON CHINA MMR VACCINE MARKET, 2013-2017
5.1 Factors Influencing Development
5.2 Forecast on Supply, 2013-2017
5.3 Forecast on Market Demand, 2013-2017
1.1 Economic Environment
1.2 Policy Environment
1.3 Chinese Population and the Structure
1.4 Overview on China Medical Industry
1.5 Overview on China Vaccine Market
2 OVERVIEW ON CHINA MMR VACCINE MARKET, 2010-2012
2.1 Epidemic Situation of Measles, Mumps and Rubella in China
2.1.1 Measles
2.1.2 Mumps
2.1.3 Rubella
2.2 MMR Vaccine Overview
2.3 Rules on Vaccination Procedures of China National Immunization Program
3 OVERVIEW ON CHINA MMR VACCINE MARKET, 2010-2012
3.1 Status of Lot Release
3.1.1 Measles Vaccine
3.1.2 Mumps Vaccine
3.1.3 Rubella Vaccine
3.1.4 MMR Vaccine
3.2 Market Scale
4 MAJOR MANUFACTURING ENTERPRISES IN CHINA MMR VACCINE MARKET, 2010-2013
4.1 Shanghai Institute of Biological Products Co., Ltd. (SIBP)
4.1.1 Enterprise Profile
4.1.2 Lot Released Volume of MMR Vaccine
4.1.3 Production Capacity of MMR Vaccine in 2013
4.2.1 Enterprise Profile
4.2.2 Lot Released Volume of MMR Vaccine, 2010-2012
4.2.3 Production Capacity of MMR Vaccine in 2013
4.3 Other Enterprises
5 FORECAST ON CHINA MMR VACCINE MARKET, 2013-2017
5.1 Factors Influencing Development
5.2 Forecast on Supply, 2013-2017
5.3 Forecast on Market Demand, 2013-2017
SELECTED CHARTS
Chart Chinese Population Size, 2001-2012
Chart Chinese Newborn Population Size, 2001-2012
Chart Structure of Health Expenditure in China, 2001-2012
Chart Health Care Expenditure Per Capita in China, 2001-2012
Chart Incidence Status of Measles in China, 2010-2012
Chart Incidence Status of Mumps in China, 2010-2012
Chart Incidence Status of Rubella in China, 2010-2012
Chart Lot Released Volume of MMR Vaccine in China, 2010-2012
Chart Market Scale of MMR Vaccine in China, 2010-2012
Chart Lot Released Volume of MMR Vaccine of Shanghai Institute of Biological Products Co., Ltd., 2010-2012
Chart MMR Vaccine of Beijing Tiantan Biological Products Co., Ltd.
Chart Forecast on Lot Released Volume of MMR Vaccines in China, 2013-2017
Chart Forecast on Market Scale of MMR Vaccines in China, 2013-2017
Chart Chinese Population Size, 2001-2012
Chart Chinese Newborn Population Size, 2001-2012
Chart Structure of Health Expenditure in China, 2001-2012
Chart Health Care Expenditure Per Capita in China, 2001-2012
Chart Incidence Status of Measles in China, 2010-2012
Chart Incidence Status of Mumps in China, 2010-2012
Chart Incidence Status of Rubella in China, 2010-2012
Chart Lot Released Volume of MMR Vaccine in China, 2010-2012
Chart Market Scale of MMR Vaccine in China, 2010-2012
Chart Lot Released Volume of MMR Vaccine of Shanghai Institute of Biological Products Co., Ltd., 2010-2012
Chart MMR Vaccine of Beijing Tiantan Biological Products Co., Ltd.
Chart Forecast on Lot Released Volume of MMR Vaccines in China, 2013-2017
Chart Forecast on Market Scale of MMR Vaccines in China, 2013-2017
